Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Summary

This study proposes that the addition of statins reduces the treatment delays or early discontinuations secondary to cardiotoxicity in patients with Stage I-III HER2 positive breast being treated with anti-HER2 therapy.

Timeline

Start

2022-09-19

Primary completion

2026-09-01

Completion

2027-03-01

Drugs

Indications